Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Simvastatin switch savings

Executive Summary

Express Scripts member plans have saved $230 million on cholesterol-fighting drugs through increased generic utilization since January 2006, the pharmacy benefit manager reports April 26. The PBM aggressively promoted therapeutic switching from Pfizer's Lipitor (atorvastatin) to Merck's Zocor (simvastatin) prior to the introduction of generic simvastatin (1"The Pink Sheet" Oct. 24, 2005, p. 19). With the launch of generic simvastatin and generic pravastatin (Bristol-Myers Squibb's Pravachol) in 2006, "use of generic cholesterol-fighting drugs has increased from eight percent to 44 percent," Express Scripts says...

You may also be interested in...

Pfizer Will Review Cholesterol Drug Category To Gauge Longevity Of Slowdown

Pfizer's annual financial analysis will include a review of the cholesterol-lowering drug market to determine if a more than 50% drop in new prescription growth rates in the third quarter is a short-term or long-term effect, CEO Hank McKinnell said

FDA’s 2021 Budget Priorities For Cosmetics, Food Programs Include AI Use In Postmarket Oversight

FDA’s food, dietary supplement and cosmetics division seeks funding to support its artificial intelligence capabilities, including post-market surveillance and speedy interventions in instances where safety issues arise. Also of note, the agency cites UV filters’ effects on the skin microbiome as a research priority in its fiscal 2021 budget justification to Congress.

Don't Take For Granted A Patient's Role In Clinical Trials, Experts Say

Catering to patients can help make clinical trials more accessible and useful, presenters argued at a recent conference.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts